Prediction programs identified two common predicted targets of miR-133b, the antiapoptotic MCL-1 and BCL-W, both of which are members of the antiapoptotic BCL-2 family [112] and have previously been reported to be increased in both solid and hematological malignancies including lung cancer [113, 114]. This evidence concerns the gene BCL2 and lung carcinoma.